Location Directory

Clinical trials in Phoenix, Arizona

This page shows live ClinicalTrials.gov search results for Phoenix, Arizona, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

8144

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Chronic Graft-versus-host-disease
Interventions: Axatilimab, Ruxolitinib, Corticosteroids; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more

Conditions: HIV-1-infection
Interventions: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 47
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 42 more

Conditions: Cow's Milk Allergy
Interventions: Experimental Extensively Hydrolyzed Formula, Placebo Extensively Hydrolyzed Formula; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 3 Months to 12 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: Phoenix, Arizona • Aurora, Colorado • Chicago, Illinois + 6 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Itepekimab SAR440340, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 75
States / cities: Birmingham, Alabama • Jasper, Alabama • Chandler, Arizona + 56 more

Conditions: Schizophrenia, Autism-Related Irritability
Interventions: KarXT, KarX-EC; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 56
States / cities: Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 47 more

Conditions: B Acute Lymphoblastic Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine; Procedure · Biological · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 366 Days to 46 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 143
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more

Conditions: Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions: Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 255
States / cities: Phoenix, Arizona • Tucson, Arizona • Dublin, California + 207 more

Conditions: High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Interventions: Zilebesiran, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 11,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 272
States / cities: Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 216 more

Conditions: Epilepsy, Epilepsy (Treatment Refractory)
Interventions: Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system); Device
Lead sponsor: Epiminder America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 15 more

Conditions: Alzheimers Disease
Interventions: No Intervention; Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 80,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 60 more

Conditions: Diabetic Macular Edema (DME)
Interventions: Remigromig, Ranibizumab; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 107
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 96 more

Conditions: Diabetic Retinopathy
Interventions: BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 40
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more

Clinical trials in Phoenix, Arizona

Filter and sort this location

Live official records

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

Infant Formula in Infants and Children With Cow's Milk Allergy

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy